Chen et al. modified the external surface of an amino-triphenyl dicarboxylate-bridged a Zr-based nanoMOF with nucleic acids complementary to an aptamer against Vascular endothelial growth factor (VEGF) before loading it with doxorubicin and then capping with the VEGF aptamer.139 This created a VEGF-responsive nanoMOF with selective uptake – compared to MCF-10A control cells – into MDA-MB-231 breast cancer cells via aptamer AS1411 mediated nucleolin binding. This evidence concerns the gene VEGFA and breast carcinoma.